epocrates logo
epocrates logo
epocrates logo
  • 0

Interaction Check

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Selected Drugs Clear All

  • remove Actos
    pioglitazone
  • remove arformoterol inhaled
    generic
  • remove Azopt
    brinzolamide ophthalmic
  • remove Emgality (galcanezumab-gnlm)
    galcanezumab
  • remove memantine
    generic
  • remove Onglyza
    saxagliptin
  • remove sodium oxybate
    generic
  • remove Toujeo
    insulin glargine

multicheck MultiCheck Results - 5 Interactions

Smiley face Smiley face

Monitor/Modify Tx

Smiley face Smiley face Actos (pioglitazone) + Onglyza (saxagliptin)

Monitor/Modify Tx


pioglitazone + saxagliptin

monitor glucose, cardiac fxn: combo may incr. risk of hypoglycemia, cardiotoxicity (additive effects)

Smiley face Smiley face Actos (pioglitazone) + Toujeo (insulin glargine)

Monitor/Modify Tx


pioglitazone + insulin

monitor glucose; consider dose adjustment of one or both drugs: combo may incr. risk of hypoglycemia, heart failure symptoms (additive effects)

Smiley face Smiley face arformoterol inhaled (generic) + Emgality (galcanezumab-gnlm) (galcanezumab)

Monitor/Modify Tx


arformoterol inhaled + galcanezumab

monitor BP: combo may incr. risk of HTN (additive effects)

Smiley face Smiley face arformoterol inhaled (generic) + Toujeo (insulin glargine)

Monitor/Modify Tx


arformoterol inhaled + insulin

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

Smiley face Smiley face Onglyza (saxagliptin) + Toujeo (insulin glargine)

Monitor/Modify Tx


saxagliptin + insulin

monitor glucose; consider dose adjustment of one or both drugs: combo may incr. risk of hypoglycemia (additive effects)

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback Cookie Preferences
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information